XQXiujuan Qu

Xiujuan Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiujuan Qu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ce Li

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, People’s Republic of China

    1 shared publication
  • Qian Dong

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People’s Republic of China

    1 shared publication
  • Qian Wang

    Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, Liaoning, 110042, People’s Republic of China

    1 shared publication
  • Yan Wang

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, People’s Republic of China

    1 shared publication
  • Yanju Ma

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China

    1 shared publication
  • Ye Zhang

    The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China

    1 shared publication

Latest Publications

  • Open Access

    Tamoxifen reverses epithelial–mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells

    by Qian Wang, Yu Cheng, Yan Wang, Yibo Fan, Ce Li, Ye Zhang, Yiding Wang, Qian Dong, Yanju Ma, Yue-E Teng, et al.

    Although the efficacy of tamoxifen (TAM) for breast cancer has been attributed to inducing cell cycle arrest and apoptosis by inhibiting estrogen receptor (ER) signaling, recent evidence indicates that TAM also possesses ER-independent antitumor activity through an unclear mechanism. The present study investigated the anti-tumor mechanism of TAM on mesenchymal triple-negative breast cancer (TNBC). The inhibitory effect of TAM on tumor migration and metastasis was analyzed by transwell chamber in vitro and by murine xenograft model in vivo. The promoter sequence of miR-200c was predicted by an online CpG island predictor. Relative expression of miR-200c was measured by quantitative real-time PCR. After treatment with TAM, mesenchymal TNBC cells (MCF-7/ADR and MDA-MB-231) morphologically changed from mesenchymal to epithelial types. Meanwhile, cell migration ability was also significantly decreased in ER-positive breast cancer cells after exposure to TAM. Consistent with these in-vitro results, TAM significantly suppressed lung metastasis rate of mesenchymal TNBC cells in murine xenograft tumors. miRNA array analysis of two types of breast cancer cells showed that miR-200c expression was inhibited in mesenchymal TNBC cells, but increased after TAM treatment due to demethylation of miR-200c promoters. Our results indicate that TAM inhibits cell migration and enhances chemosensitivity of mesenchymal TNBC cells by reversing their EMT-like property; and that this EMT-reversal effect results from upregulation of miR-200c through demethylating its promoter. To our knowledge, this is the first explanation of a non-ER-related mechanism for the effect of TAM on mesenchymal TNBC cells.